Please try another search
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase II clinical trial for the treatment of chronic inflammatory disorders; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressed on the surface of solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. In addition, it is developing Tripokin, a fully-human immunostimulatory product consisting of tumor necrosis factor and interleukin-2 fused into one molecular entity, which is in preclinical stage. Philogen S.p.A. was founded in 1996 and is based in Siena, Italy.
Name | Age | Since | Title |
---|---|---|---|
Maria Angela Fantini | - | 2021 | Auditor |
Roberto Bonini | - | 2021 | Auditor |
Duccio Neri | - | 1996 | Co-Founder & Executive Chairman |
Stefano Mecacci | - | - | Chairman of Statutory Auditor |
Roberto Ferraresi | - | 2019 | Independent Director |
Sergio Gianfranco Luigi Maria Dompé | - | - | Director |
Guido Guidi | 68 | 2019 | Member of Scientific Advisory Board & Director |
Marta Bavasso | - | - | Lead Independent Director |
Cornelia Halin Winter | - | - | Member of Scientific Advisory Board |
Leopoldo Giampaolo Zambeletti | 54 | - | Director |
Wolfgang Berdel | - | - | Member of Scientific Advisory Board |
Nathalie Francesca Maria Dompé | 36 | - | Director |
Maria Giovanna Calloni | 58 | 2022 | Director |
Dario Neri | 60 | 1996 | Co-Founder, CEO , MD, CSO, President of the Scientific Advisory Board & Director |
Pierluigi Matteoni | - | - | Standing Auditor |
Alessandra Pinzuti | - | 2021 | Standing Auditor |
Giovanni Neri | - | - | Co-Founder, Head of IP & Licensing and Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review